<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433368</url>
  </required_header>
  <id_info>
    <org_study_id>OA001</org_study_id>
    <nct_id>NCT00433368</nct_id>
  </id_info>
  <brief_title>Efficacy of L-Ornithine-L-Aspartate in Cirrhotics With Hepatic Encephalopathy</brief_title>
  <official_title>Efficacy of a Three Days' Infusion of L-Ornithine-L-Aspartate as an Adjuvant Therapy in Cirrhotic Patients With Overt Hepatic Encephalopathy: A Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aga Khan University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether L-Ornithine L-Aspartate is effective for&#xD;
      the improvement of Overt Hepatic Encephalopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no effective treatment available for hepatic encephalopathy at the moment; therefore&#xD;
      we aimed to check the efficacy and safety of L-ornithine L-aspartate(LOLA). It provides&#xD;
      critical substrates for ureagenesis and glutamine synthesis, the two primary mechanisms by&#xD;
      which the body rids itself of excess ammonia. Ornithine is a specific activator of ornithine&#xD;
      carbamyl transferase and carbamylphosphate synthetase, and, in addition, is a substrate for&#xD;
      ureagenesis. These reactions are carried out mainly in the periportal portion of the hepatic&#xD;
      lobules. Aspartate and ornithine, after conversion to alfa-ketoglutarate, are substrates for&#xD;
      glutamine synthesis, which is performed exclusively by a small population of perivenous&#xD;
      hepatocytes, the so-called perivenous scavenger cells. The ammonia lowering effect resulting&#xD;
      from the stimulation of these two basic mechanisms of ammonia detoxification has been studied&#xD;
      in animals and was confirmed in humans in clinical trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date>September 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in HE grade.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>deterioration in HE grade.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting ammonia level and</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate</measure>
  </secondary_outcome>
  <enrollment>108</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Ornithine L-Aspartate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cirrhosis, diagnosed on the basis of clinical findings, sonographic, and/or histologic&#xD;
             basis,&#xD;
&#xD;
          -  Patients &gt;14 years, with HE grades 1 to 4 according to West Haven Criteria,&#xD;
&#xD;
          -  Hyperammonemia (fasting venous blood ammonia level &gt;60 µmol/l), and&#xD;
&#xD;
          -  Patients with a single reversible precipitating factor of HE such as constipation,&#xD;
             hypokalemia, urinary tract infection, respiratory tract infection, spontaneous&#xD;
             bacterial peritonitis (SBP), dehydration, or none.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hepatocellular carcinoma,&#xD;
&#xD;
          -  severe septicemia,&#xD;
&#xD;
          -  active gastrointestinal bleeding,&#xD;
&#xD;
          -  hepatorenal syndrome,&#xD;
&#xD;
          -  acute superimposed liver injury,&#xD;
&#xD;
          -  advanced cardiac or pulmonary disease and end stage renal failure,&#xD;
&#xD;
          -  patients with minimal HE&#xD;
&#xD;
          -  patients taking sedatives, antidepressants, or benzodiazepines and&#xD;
&#xD;
          -  patients with chronic HE on metronidazole or lactulose prior to admission.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wasim Jafri, MD; FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Chairman Department of Medicine, Aga Khan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shahab Abid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor, Department of Medicine, Aga Khan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aga Khan University Hospital</name>
      <address>
        <city>Karachi</city>
        <state>Sind</state>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <results_reference>
    <citation>[1] ] STAEDT U, LEWELING H, GLADISCH R, KORTSIK C, HAGMULLER E, HOLM E. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol 1993;19(3): 424-430. [2] KIRCHEIS G, NILIUS R, HELD C, BERNDT H, BUCHNER M, GÖRTELMEYER R, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997;25(6):1351-1360. [3] FEHÉR J, LÁNG I, GÓGL A, VARGA L, TOMPOS G, PRÓNAI L. Effect of ornithine-aspartate infusion on elevated serum ammonia concentration in cirrhotic patients - results of a randomized, placebo-controlled double-blind multicentre trial. Med Sci Monit 1997; 3(5):669-673. [4] KIRCHEIS G, WETTSTEIN M, VOM DAHL S, HÄUSSINGER D. Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Met Brain Dis 2002;17(4): 453-462. [5] REES CJ, OPPONG K, AL MARDINI H, HUDSON M, RECORD CO. Effect of L- ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut 2000; 47(4): 571-574.</citation>
  </results_reference>
  <verification_date>February 2007</verification_date>
  <study_first_submitted>February 8, 2007</study_first_submitted>
  <study_first_submitted_qc>February 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2007</study_first_posted>
  <last_update_submitted>February 8, 2007</last_update_submitted>
  <last_update_submitted_qc>February 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2007</last_update_posted>
  <keyword>L-ornithine-L-aspartate,</keyword>
  <keyword>porto-systemic encephalopathy,</keyword>
  <keyword>hepatic encephalopathy,</keyword>
  <keyword>liver cirrhosis,</keyword>
  <keyword>mental state</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methylaspartate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

